← Back to Clinical Trials
Recruiting Phase 3 NCT06707103

Tissue Repair Gel in Venous Leg Ulcers in AU/US

Trial Parameters

Condition Venous Leg Ulcer
Sponsor TR Therapeutics
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 312
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-04
Completion 2026-12
Interventions
TR987 0.1% gel + Standard of CareStandard of care

Brief Summary

The goal of this clinical trial is to learn if TR987 0.1% gel + Standard of Care works better than Standard of Care alone to treat Venous Leg Ulcers (VLUs). It will also provide additional information about the safety of drug TR987 0.1% gel.

Eligibility Criteria

Inclusion Criteria: * Adults 18 years and older * Venous insufficiency has been clinically diagnosed clinically and medically confirmed. * Females who are neither pregnant nor breastfeeding and if of child-bearing potential are on an acceptable method of birth control. * The Venous Ulcer should be between 2 cm2 and 12 cm2 at randomization. * Target ulcer age must be ≥ 4 weeks at Screening. * Participants must have adequate arterial flow as confirmed by ABI/TBI, TB, SPP, TCPo2, or Duplex Doppler. * Body mass index (BMI) ≤ 50 kg/m2. * HbA1C ≤12%. Exclusion Criteria: * Target ulcer has been treated with prohibited medications or therapies. * History of radiation at the target ulcer site. * Target ulcer decreases in area by 30% or more during screening period. * History of osteomyelitis at the target ulcer within 6 months of screening. * History of cancer in the preceding 5 years (except as noted in the protocol). * Participants considered nutritionally deficient.

Related Trials